Thromboembolism in gynecologic oncology.
The risk of thrombo-embolic complications increases in surgical gynaecological oncology as a consequence of difficult and long-lasting interventions. In gynaecologic operations without any drug prophylaxis thrombosis has been reported by 24-29%, whereas in operations of progressed oncological findings thrombo-embolic complications arise in almost every second case. Such complications have to be taken seriously due to difficulty treatable sequelae (post-thrombic syndrome) and due to potentially lethal pulmonary embolism. Furthermore, they are important causes of postoperative early mortality. Diagnosis of a deep thrombosis is insecure even for experienced clinicians. We have various diagnostical means at our disposal, such as phlebography, sounding and 125-iodine-fibrinogen-testing. Differentiated drug medication for the prevention and therapy of thrombo-embolism is definitely indicated. There are also different kinds of physical and drug-aided means, which can be applied according to the individual situation.
Heidegger
H
H
Dept. Obst. Gyn. Klinikum Bamberg.
von Hugo
R
R
Graeff
H
H
D003374:Coumarins / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000150:complications*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D011183:Postoperative Complications; D011237:Predictive Value of Tests; D011655:Pulmonary Embolism / Q000517:prevention & control; D012680:Sensitivity and Specificity; D013923:Thromboembolism / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
D003374:Coumarins; D003911:Dextrans; D006493:Heparin